

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	
Background	9
Objective and Scope	9
Selection of Topics for Monographs.....	10
Data for Monographs	11
The Working Group.....	11
Working Procedures.....	11
Exposure Data.....	12
Studies of Cancer in Humans.....	14
Studies of Cancer in Experimental Animals.....	17
Other Data Relevant to an Evaluation of Carcinogenicity and Its Mechanisms.....	20
Summary of Data Reported	21
Evaluation	23
References.....	27
THE MONOGRAPHS	
Printing processes and printing inks	33
1. Exposure data	33
1.1 Historical overview.....	33
1.2 Description of the industry	35
1.2.1 Printing ink manufacture	35
1.2.2 The printing processes	36
(a) Lithography.....	36
(b) Letterpress.....	38
(c) Flexography	38
(d) Gravure	39
(e) Screen process.....	39
1.3 Chemistry and uses of printing inks	40
1.3.1 Pigments	40
1.3.2 Vehicles and ink drying.....	42
1.3.3 Printing inks and processes.....	42
(a) Lithographic (offset) inks	42
(b) Letterpress inks	44

	(c) Flexographic inks.....	44
	(d) Gravure inks.....	45
	(e) Screen process inks.....	46
1.4	Production.....	46
1.5	Occupational exposures in the printing processes and to printing inks.....	47
1.5.1	Exposures in printing ink manufacture.....	49
1.5.2	Exposures in printing operations.....	54
1.6	Regulations and guidelines.....	58
2.	Studies of cancer in humans.....	59
2.1	Ecological studies.....	60
2.2	Community-based studies.....	61
2.2.1	Death certificate studies.....	61
2.2.2	Record-linkage studies.....	63
2.2.3	Case-control studies.....	66
	(a) Cancer at multiple sites.....	66
	(b) Urinary bladder cancer.....	72
	(c) Lung cancer.....	77
	(d) Lymphohaematopoietic neoplasms.....	86
	(e) Oropharyngeal cancer.....	86
	(f) Testicular cancer.....	87
	(g) Other cancer sites.....	87
2.2.4	Cohort studies.....	93
2.3	Industry-based studies.....	93
2.4	Childhood cancer in relation to parental exposure.....	106
3.	Studies of cancer in experimental animals.....	108
	Subcutaneous injection.....	108
4.	Other data relevant to an evaluation of carcinogenicity and its mechanisms.....	109
4.1	Absorption, distribution, excretion and metabolism.....	109
4.2	Toxic effects.....	109
4.2.1	Humans.....	109
4.2.2	Experimental systems.....	112
4.3	Reproductive and developmental effects.....	113
4.3.1	Humans.....	113
	(a) Cohort study.....	113
	(b) Case-control studies of congenital anomalies.....	114
	(c) Case-control study of infertility.....	119
	(d) Case-control study of mental retardation.....	119
4.3.2	Experimental systems.....	120
4.4	Genetic and related effects.....	120
4.4.1	Humans.....	121
	(a) Urinary mutagenicity.....	121
	(b) Cytogenetic damage in lymphocytes.....	121
4.4.2	Experimental systems.....	124

5. Summary of data reported and evaluation.....	125
5.1 Exposure data	125
5.2 Human carcinogenicity data	126
5.3 Animal carcinogenicity data	130
5.4 Other relevant data.....	130
5.5 Evaluation.....	131
6. References	132
Carbon black	149
Some nitro compounds	
2-Chloronitrobenzene, 3-chloronitrobenzene and 4-chloronitrobenzene	263
3,7-Dinitrofluoranthene and 3,9-dinitrofluoranthene	297
2,4-Dinitrotoluene, 2,6-dinitrotoluene and 3,5-dinitrotoluene.....	309
2-Nitroanisole	369
Nitrobenzene	381
2-Nitrotoluene, 3-nitrotoluene and 4-nitrotoluene	409
Tetranitromethane	437
2,4,6-Trinitrotoluene	449
Musk ambrette and musk xylene	477
SUMMARY OF FINAL EVALUATIONS	497
APPENDIX 1. SUMMARY TABLES OF GENETIC AND RELATED EFFECTS	499
APPENDIX 2. ACTIVITY PROFILES FOR GENETIC AND RELATED EFFECTS	521
SUPPLEMENTARY CORRIGENDA TO VOLUMES 1-64	549
CUMULATIVE INDEX TO THE MONOGRAPHS SERIES	551

NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.